Precision For Medicine

Heading to San Diego? Don’t miss us at ASH Booth 2021 As the global incidence of hematologic cancers rises, Precision teams generate insights that impact outcomes, combining deep heme-onc expertise, operational excellence, and leading-edge technology. Learn how integrated CRO services can drive success for your program.

Did you know gratitude benefits for your overall wellbeing? It strengthens our feelings of connection, alleviates depression, and increases our sense of engagement with the world around us. As we reflect on what we are thankful for, we wish our friends, family, and colleagues a holiday season brimming with gratitude. We especially want to express our appreciation to our employees and clients for their boundless enthusiasm and tireless commitment to advancing the medical treatments that improve the quality of life for patients in need.

This new video in honor of Lung Cancer Awareness Month reminds us that having a CMO from the FDA can be a “secret weapon” for today’s life sciences innovators. We’re proud to share insights from our Chief Medical Officer, Harpreet Singh, MD, on the progress that’s been made in non-small cell lung cancer. From her time at the FDA to her work at Precision for Medicine, Dr. Singh remains at the forefront of advancing life-saving treatments. Watch this special edition of CMO Confidential and follow Harpreet Singh, MD, to hear more about the breakthroughs shaping the future of cancer care. #FDA #LungCancerAwarenessMonth #lungcancer #lifesciences

You’ve climbed the ladder, now take the next step… Get more out of your career as an Executive Director, Medical Oncology at Precision: https://hubs.ly/Q02ZfXvj0 hashtag#pharmajobs hashtag#clinicalresearch hashtag#oncology hashtag#womeninscience

Earlier this month, the Project Farma (PF) team gathered in Nashville for our annual CARES Weekend to 'Amplify Our Impact'. Here are some of the highlights: ? The Importance of Patient Centricity panel feat. Project Farma EVP Tony Khoury, Audrey Greenberg, and Brett Kopelan ? Interactive workshops with Second City Works to enhance our emotional intelligence ? Professional development workshops and presentations led by our executive leadership team ? Building Cancer Care Kits for children and caregivers at Ronald McDonald House Charities of Nashville ? Live music, dinner, and networking along Broadway ? Memorable closing dinner at Nissan Stadium Here's a first look at photos of our team in action! #PatientFocused #PeopleFirst #ProfessionalDevelopment #AmplifyingOurImpact

Optimizing immunohistochemistry validation is essential for reliable biomarker detection in clinical settings. Robust validation protocols and strategic regulatory planning ensure assay reliability and compliance. Learn about the critical steps for successful clinical trials and assay commercialization by reading the full article. https://hubs.ly/Q02Z8Xv30 #IHC #Biomarkers #ClinicalTrials

Congratulations to Precision's Darren W. Davis, PhD on his presentation at AMP yesterday with Agena Bioscience presenting methods to bridge critical gaps in detecting mutations not identified by next-generation sequencing (NGS) alone. Got questions for Darren or our team? Stop by Booth 1311 or reach out to set up time to speak with Darren Davis, Glen Ferguson, Rob Fannon, Kristi Garner and Brian Hart. #AMP2024

NEW FDA VIDEO ROUNDUP: In the latest edition of CMO Confidential, Harpreet Singh, MD, discusses the notable regulatory milestones in oncology and rare disease treatments from October. The FDA's approval of Zolbetuximab (Vyloy) for gastric and gastroesophageal junction adenocarcinoma marked a step forward in targeted therapies, particularly for patients with CLDN18.2 expression. This approval highlights the importance of biomarker-driven treatments in oncology and has implications for the future. The FDA released an update on the Rare Disease Innovation Hub aimed at streamlining the development of treatments for rare diseases. See why this is good news for innovators in the rare disease space. In hematology, Asciminib (Scemblix) received accelerated approval for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia. The substantial improvements in response rates compared to the investigator-selected tyrosine kinase inhibitors (IS-TKIs) is very noteworthy. Watch now and follow Harpreet Singh, MD for future insights.

Why are global drug developers choosing Australia to expedite clinical trials? (The answer goes beyond regulations.) Australia is known for its efficient trial environment, but navigating its unique landscape requires expertise. In this article, we explore the processes, partnerships, and precision that allow us to get trials up and running faster than ever. Read up on down under: https://hubs.ly/Q02Z1NTC0 #australia #clinicaltrials #clinicalresearch

The Precision team would love to meet you at EBF this week! Stop by Booth 2H or reach out to set up time to speak with Mandy Higgins or Astrid Grunwald.